Head-to-head evidence
SAR443579 vs Tagraxofusp
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: CD123 · full Acute Myeloid Leukemia pipeline
SAR443579
Developed by Sanofi
NCT05086315 · Phase 1/2 · terminated
This was an open-label, non-randomized, single-arm, first-in-human dose-escalation study of SAR443579 in relapsed or refractory acute leukemias and related blood cancers, with no control group. The primary goal was to find a safe dose by tracking dose-limiting toxicities, not to test efficacy, and the study was terminated before most of its planned expansion cohorts began.
Tagraxofusp
Marketed by Stemline Therapeutics, Inc.
NCT02113982 · Phase 1/2 · completed
The study was non-randomized, open-label, single-arm, and had no comparator; although complete response is a clinical disease outcome, the main efficacy cohort included only 13 patients. Its reported response rate therefore provides limited controlled evidence for tagraxofusp, and no formal between-treatment primary endpoint comparison was applicable.
Next expected readout: April 2027 · NCT06498973 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SAR443579's landscape · Tagraxofusp's landscape